<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359800</url>
  </required_header>
  <id_info>
    <org_study_id>ISS OBS T-004</org_study_id>
    <nct_id>NCT01359800</nct_id>
  </id_info>
  <brief_title>Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients</brief_title>
  <acronym>ISS OBS T-004</acronym>
  <official_title>A Multicentre, Observational, Cross-sectional Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients in Selected Areas of Gauteng and Eastern Cape</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ensoli, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Italian Ministry of Foreign Affairs - Dir. Gen. for Cooperation and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Superiore di Sanità</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tat is a key HIV regulatory protein produced very early after infection, prior to virus
      integration, and necessary for viral gene expression, cell-to-cell virus transmission and
      disease progression. Previous studies in natural HIV infection, indicated that the presence
      of a Tat-specific immune response correlates with a lower incidence and reduced risk of
      progression to AIDS as compared to anti-Tat negative individuals suggesting that an immune
      response to Tat may exert a protective role and control the progression to AIDS in vivo.

      On the basis of the above mentioned consideration, the present study was directed at
      investigating the seroprevalence of anti-Tat antibodies in HIV-infected South African
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, cross-sectional study aimed at assessing the frequency, magnitude
      and quality of the anti-Tat antibody response in both antiretroviral (ARV)-treated and
      treatment-naïve HIV-infected South African adults, and at exploring the correlation between
      the presence of anti-Tat antibody response and the immunological status of participants as
      well as with the presence of co-infections such as HBV, syphilis and HPV (the latter only for
      female participants).

      The study has involved 531 participants and provided important information for the planning,
      design and conduction of future therapeutic clinical trials with the Tat-based HIV vaccine in
      South African individuals.

      This study is conducted in the frame of the Government-to-Government cooperation program N.
      AID 8421, funded by the Italian Ministry of Foreign Affairs-Directorate General for
      Development Cooperation (MAE-DGCS) and jointly implemented by the Italian Istituto Superiore
      di Sanita' (ISS) and the South African Department of Health in collaboration with the South
      African AIDS Vaccine Initiative of the Medical Research Council (MRC-SAAVI)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Tat Antibody Responses</measure>
    <time_frame>Up to 14 months</time_frame>
    <description>Assessment of serum anti-Tat antibodies. Anti-Tat humoral immune response will include the determination of serum IgM, IgG and IgA antibodies against both clade B- and C-derived Tat proteins and titration of IgM, IgG and IgA anti-Tat antibodies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological status of anti-Tat positive and negative participants</measure>
    <time_frame>Up to 14 months</time_frame>
    <description>HIV viral load and clinical status on anti-Tat+ versus anti-Tat- participants. The effect of ARV treatment non-compliance on viral load in anti-Tat+ versus anti-Tat- participants has been evaluated within the ARV-treated study group on the basis of the relevant available information.
Hepatitis B, Syphilis, HPV co-infections Assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological status of anti-Tat positive and negative participants</measure>
    <time_frame>Up to 14 months</time_frame>
    <description>Assessment of CD4 T cell counts. Exploratory immunological assays may be performed on available residual samples for a more in-depth characterisation of the immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune activation status of anti-Tat positive and negative participants</measure>
    <time_frame>Up to 14 months</time_frame>
    <description>Assessment of Immune-activation markers on CD4+ and CD8+ T cells (CD25+, CD38+ and HLA-DR+).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">531</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Treatment-naive HIV+ subjects</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HAART-treated HIV+ subjects</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, cervical samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV positive, ARV-treated and treatment-naïve participants.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected individuals Aged 18-45 years Participants enrolled into the ARV-treated
             group must have been on treatment for not less than 3 months.

        Exclusion Criteria:

          -  Unwillingness to consent to study inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara BE Ensoli, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Istituto Superiore di Sanità</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Sisulu University HIV Vaccine Research Unit</name>
      <address>
        <city>Mthatha</city>
        <state>Eastern Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mecru Clinical Research Unit (MeCRU)</name>
      <address>
        <city>Medunsa</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://www.hiv1tat-vaccines.info</url>
  </link>
  <link>
    <url>http://www.iss.it/aids/</url>
  </link>
  <reference>
    <citation>Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Tripiciano A, Longo O, Bellino S, Francavilla V, Paniccia G, Arancio A, Scoglio A, Collacchi B, Ruiz Alvarez MJ, Tambussi G, Tassan Din C, Palamara G, Latini A, Antinori A, D'Offizi G, Giuliani M, Giulianelli M, Carta M, Monini P, Magnani M, Garaci E. The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine. 2009 Dec 11;28(2):371-8. doi: 10.1016/j.vaccine.2009.10.038. Epub 2009 Oct 29.</citation>
    <PMID>19879233</PMID>
  </reference>
  <reference>
    <citation>Longo O, Tripiciano A, Fiorelli V, Bellino S, Scoglio A, Collacchi B, Alvarez MJ, Francavilla V, Arancio A, Paniccia G, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine. 2009 May 26;27(25-26):3306-12. doi: 10.1016/j.vaccine.2009.01.090. Epub 2009 Feb 7.</citation>
    <PMID>19208456</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, Arancio A, Ariola C, Ruiz Alvarez MJ, Campagna M, Scaramuzzi D, Iori C, Esposito R, Mussini C, Ghinelli F, Sighinolfi L, Palamara G, Latini A, Angarano G, Ladisa N, Soscia F, Mercurio VS, Lazzarin A, Tambussi G, Visintini R, Mazzotta F, Di Pietro M, Galli M, Rusconi S, Carosi G, Torti C, Di Perri G, Bonora S, Ensoli F, Garaci E. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One. 2010 Nov 11;5(11):e13540. doi: 10.1371/journal.pone.0013540.</citation>
    <PMID>21085635</PMID>
  </reference>
  <reference>
    <citation>Bellino S, Francavilla V, Longo O, Tripiciano A, Paniccia G, Arancio A, Fiorelli V, Scoglio A, Collacchi B, Campagna M, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials. 2009 Sep;4(3):195-204. Review.</citation>
    <PMID>20028332</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Monini P, Magnani M, Garaci E. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS. 2008 Oct 18;22(16):2207-9. doi: 10.1097/QAD.0b013e32831392d4.</citation>
    <PMID>18832884</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Fiorelli V, Ensoli F, Cafaro A, Titti F, Buttò S, Monini P, Magnani M, Caputo A, Garaci E. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS. 2006 Nov 28;20(18):2245-61. Review.</citation>
    <PMID>17117011</PMID>
  </reference>
  <reference>
    <citation>Buttò S, Fiorelli V, Tripiciano A, Ruiz-Alvarez MJ, Scoglio A, Ensoli F, Ciccozzi M, Collacchi B, Sabbatucci M, Cafaro A, Guzmán CA, Borsetti A, Caputo A, Vardas E, Colvin M, Lukwiya M, Rezza G, Ensoli B; Tat Multicentric Study Group. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis. 2003 Oct 15;188(8):1171-80. Epub 2003 Sep 30.</citation>
    <PMID>14551888</PMID>
  </reference>
  <reference>
    <citation>Rezza G, Fiorelli V, Dorrucci M, Ciccozzi M, Tripiciano A, Scoglio A, Collacchi B, Ruiz-Alvarez M, Giannetto C, Caputo A, Tomasoni L, Castelli F, Sciandra M, Sinicco A, Ensoli F, Buttò S, Ensoli B. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis. 2005 Apr 15;191(8):1321-4. Epub 2005 Mar 14.</citation>
    <PMID>15776379</PMID>
  </reference>
  <reference>
    <citation>Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology. 2014 Jun 24;11:49. doi: 10.1186/1742-4690-11-49.</citation>
    <PMID>24961156</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Cafaro A, Monini P, Marcotullio S, Ensoli F. Challenges in HIV Vaccine Research for Treatment and Prevention. Front Immunol. 2014 Sep 8;5:417. doi: 10.3389/fimmu.2014.00417. eCollection 2014. Review.</citation>
    <PMID>25250026</PMID>
  </reference>
  <reference>
    <citation>Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology. 2015 Apr 29;12:33. doi: 10.1186/s12977-015-0151-y.</citation>
    <PMID>25924841</PMID>
  </reference>
  <reference>
    <citation>Cafaro A, Tripiciano A, Sgadari C, Bellino S, Picconi O, Longo O, Francavilla V, Buttò S, Titti F, Monini P, Ensoli F, Ensoli B. Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine. Expert Opin Biol Ther. 2015;15 Suppl 1:S13-29. doi: 10.1517/14712598.2015.1021328. Epub 2015 Jun 22. Review.</citation>
    <PMID>26096836</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2011</study_first_submitted>
  <study_first_submitted_qc>May 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Superiore di Sanità</investigator_affiliation>
    <investigator_full_name>Barbara Ensoli, MD</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HAART</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

